Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area
Latest Information Update: 08 May 2020
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Apr 2020 Status changed to completed.
- 19 Jul 2016 New trial record